Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28977937 | 0.96 | ALDH1A1 (0.43) | ALDH1A1LMNASLC15A2CA4TSHR | |
| SCHEMBL285627 | 0.87 | CA4 (0.48) | LMNACA4TSHRPEPD | |
| SCHEMBL27473070 | 0.85 | CA4 (0.46) | CA4TSHRPEPD | |
| SCHEMBL1643232 | 0.85 | CA4 (0.46) | CA4TSHRPEPD | |
| SCHEMBL28977939 | 0.81 | BTN3A1 (0.42) | ALDH1A1LMNASLC15A2BTN3A1 | |
| SCHEMBL8561065 | 0.78 | LMNA (0.45) | LMNASLC15A2CA4TSHRPEPD | |
| Phosphonic Acid SCHEMBL7991199 | 0.78 | CA4 (0.40) | CA4TSHRPEPD | |
| SCHEMBL18696078 | 0.78 | MGAM (0.52) | ALDH1A1CA4TSHRPEPDMGAM | |
| SCHEMBL60769 | 0.78 | ALDH1A1 (0.52) | ALDH1A1LMNACA4TSHRPEPD | |
| SCHEMBL2201756 | 0.77 | TSHR (0.43) | CA4TSHRPEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352466-A1 | APTAMER-siRNA FUSIONS | APTERNA LIMITED (GB) | 2024-10-24 | — | — | US | disclosed |
| CN-118006613-A | Aptamer-siRNA fusions | 艾普特纳有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4361271-A2 | APTAMER-SIRNA FUSIONS | Apterna Limited (GB) | 2024-05-01 | — | — | EP | disclosed |
| US-20240052355-A1 | APTAMER-siRNA FUSIONS | APTERNA LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| US-10801050-B2 | Microorganism modified for the assimilation of levulinic acid | METABOLIC EXPLORER (FR) | 2020-10-13 | — | — | US | disclosed |
| EP-3365427-B1 | MICROORGANISM MODIFIED FOR THE ASSIMILATION OF LEVULINIC ACID | METABOLIC EXPLORER SA (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-20180312890-A1 | MICROORGANISM MODIFIED FOR THE ASSIMILATION OF LEVULINIC ACID | METABOLIC EXPLORER (FR) | 2018-11-01 | — | — | US | disclosed |
| EP-3365427-A1 | MICROORGANISM MODIFIED FOR THE ASSIMILATION OF LEVULINIC ACID | Metabolic Explorer (FR) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068385-A1 | MICROORGANISM MODIFIED FOR THE ASSIMILATION OF LEVULINIC ACID | METABOLIC EXPLORER (FR) | 2017-04-27 | — | — | WO | disclosed |
| EP-2305237-B1 | THERAPEUTIC AGENT FOR MALE STERILITY | SBI PHARMACEUTICALS CO LTD (JP) | 2014-04-30 | — | — | EP | disclosed |
| CN-102014847-B | Dental composition and composite resin | KURARAY MEDICAL INC | 2013-12-04 | — | — | CN | disclosed |
| US-8563605-B2 | Therapeutic agent for male sterility | SBI PHARMACEUTICALS CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| CN-102083403-B | Dental composition and composite resin | KURARAY MEDICAL INC | 2013-10-09 | — | — | CN | disclosed |
| CN-102014848-B | Dental composition and composite resin | KURARAY MEDICAL INC | 2013-06-19 | — | — | CN | disclosed |
| CN-102083403-A | Dental composition and composite resin | KURARAY MEDICAL INC | 2011-06-01 | — | — | CN | disclosed |
| CN-102014847-A | Dental composition and composite resin | KURARAY MEDICAL INC | 2011-04-13 | — | — | CN | disclosed |
| CN-102014848-A | Dental composition and composite resin | KURARAY MEDICAL INC | 2011-04-13 | — | — | CN | disclosed |
| EP-2305237-A1 | THERAPEUTIC AGENT FOR MALE STERILITY | SBI ALApromo Co., Ltd. (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20110065787-A1 | THERAPEUTIC AGENT FOR MALE STERILITY | SBI ALApromo., Ltd. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240052355-A1 | APTAMER-siRNA FUSIONS | TFRC, CNBP, CEBPZ | ALDH1A1 3477/4885LMNA 1586/4885SLC15A2 1374/4885 |
| US-20240352466-A1 | APTAMER-siRNA FUSIONS | TFRC, CEBPZ, CNBP | ALDH1A1 3524/4885LMNA 1671/4885SLC15A2 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.